Form 8-K - Current report:
SEC Accession No. 0001326110-25-000112
Filing Date
2025-08-05
Accepted
2025-08-05 07:17:16
Documents
14
Period of Report
2025-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibrx-20250805.htm   iXBRL 8-K 30635
2 EX-99.1 ibrx-202585x8kexhibit991.htm EX-99.1 132238
6 IMMUNITYBIO LOGO image_0.jpg GRAPHIC 2549
  Complete submission text file 0001326110-25-000112.txt   299878

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ibrx-20250805.xsd EX-101.SCH 1807
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ibrx-20250805_lab.xml EX-101.LAB 21876
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ibrx-20250805_pre.xml EX-101.PRE 12528
16 EXTRACTED XBRL INSTANCE DOCUMENT ibrx-20250805_htm.xml XML 2718
Mailing Address 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121
Business Address 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121 (844) 696-5235
ImmunityBio, Inc. (Filer) CIK: 0001326110 (see all company filings)

EIN.: 431979754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37507 | Film No.: 251182793
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)